Since the company’s news of the delay in relaunch of Lotus Edge on November 28, 2017, Boston Scientific (BSX) stock has fallen ~7.8%.
According to Boston Scientific, the delay will have no material impact on the company’s fiscal 4Q17 and 2017 results.
Boston Scientific (BSX) announced the delay in the commercialization timelines of BSX’s Lotus devices in Europe and the US on November 28, 2017.
Boston Scientific (BSX) stock fell ~7.5% on November 28, 2017, triggered by the speculation of bad news.
According to a recent Reuters survey, which included eight investment brokerage firms, six (or 75%) of them have recommended a “hold” for VAR stock.
Varian Medical Systems expects to see fiscal 2018 revenue growth in the range of 2%–4%. Its adjusted diluted EPS (earnings per share) for fiscal 2018 is expected to be $4.20–$4.32.
Varian Medical Systems (VAR) spun off its imaging components business into Varex Imaging in January 2017, thus strengthening its positioning in the oncology market.
In fiscal 4Q17, Varian Medical Systems (VAR) registered a gross profit margin of 42.3% of its total sales, representing a decline of 50 basis points.
Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.
Varian Medical Systems (VAR) received FDA (U.S. Food & Drug Administration) approval in June 2017 for its Halcyon system.
Varian Medical Systems (VAR) registered a YoY (year-over-year) sales decline of ~1% in fiscal 4Q17, which was reported on October 25, 2017.
On November 30, 2017, Varian Medical Systems (VAR) was trading at its 52-week high of $111.40. On November 29, it ended trading at $111.20, its highest closing price for the last 52 weeks.
In fiscal 2Q18, Medtronic used a portion of its divestiture proceeds toward stock buybacks. The total share repurchases in the quarter came in at ~$568.0 million.
Medtronic provides solutions to hospitals, which translate the clinical value to economic value for these hospitals.
In fiscal 2Q18, Medtronic registered sales of ~$1.1 billion from emerging markets.
In fiscal 2Q18, Medtronic’s Restorative Therapies Group business registered year-over-year sales growth of ~2.0%, which came in below expectations due to the negative impact of Hurricane Maria.
Due to the disappointing fiscal 2Q18 results, Medtronic made a downward revision to its estimates for MITG sales growth in fiscal 2018 to 3.0%–3.5%.
Medtronic’s CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.
Previously, we discussed Symantec’s (SYMC) acquisition announcement of SurfEasy. After the acquisition, Symantec aims to integrate SurfEasy into its Consumer Digital Safety segment, which includes Norton and LifeLock. SurfEasy’s VPN (virtual private network)…